Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis

Immune checkpoint inhibitor (ICI)-based combinations have become the new standard of primary systemic treatment for metastatic renal cell carcinoma patients. We performed a meta-analysis aimed at evaluating ICIs plus tyrosine kinase inhibitors (TKIs) combinations across International Metastatic Rena...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Immunotherapy 2021-06, Vol.13 (9), p.783-793
Hauptverfasser:	Rizzo, Alessandro, Mollica, Veronica, Santoni, Matteo, Rosellini, Matteo, Marchetti, Andrea, Ricci, Angela Dalia, Grilli, Giada, Greco, Alba, Montironi, Rodolfo, Ardizzoni, Andrea, Massari, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use axitinib Carcinoma, Renal Cell - drug therapy Humans immune checkpoint inhibitors Immune Checkpoint Inhibitors - administration & dosage immunotherapy Kidney Neoplasms - drug therapy Molecular Targeted Therapy - methods Protein Kinase Inhibitors - administration & dosage renal cell carcinoma tyrosine kinase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!